Pricing
Sign up

Ribozyme Pharmaceuticals

Go to market map
Similar Companies
+3 more
Sign in for full access
Short description
Ribozyme Pharmaceuticals is a biotechnology company that develops therapeutics based on RNA interference (RNAi) technology.
Description
Ribozyme Pharmaceuticals is a biotechnology company. It develops therapeutics based on RNA interference (RNAi) technology. The company provides research, preclinical, and clinical development services with product candidates in various areas including age-related macular degeneration (AMD), chronic hepatitis, dermatology, asthma, Huntington’s disease (HD), oncology, and diabetes. It offers Sirna-027, which completed phase I clinical trial and is used for the treatment of AMD; Sirna-034, which is under preclinical stage and is used for the treatment of hepatitis C virus; and various drugs under preclinical stage of development for asthma, HD, chronic hepatitis, diabetes, and dermatology. The company has strategic alliances with Allergan, Inc., Eli Lilly and Company, Targeted Genetics, Protiva, Archemix Corporation, and GlaxoSmithKline. Ribozyme Pharmaceuticals was founded in 1992 and is headquartered in San Francisco, California. As of March 5, 2014, it operates as a subsidiary of Alnylam Pharmaceuticals.
Last funding
Noaccess
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
Boulder, Colorado, United States, North America
Founded on
January 1, 1992
Non-profit?
No
Acquired?
No
Employees count
1-10
Revenue range
$34056 - 789030
Sign in for full access
Investors
Noaccess
Sign in for full access